NANura Abubakar

Nura Abubakar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nura Abubakar has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review

    by Nura Bello, Shuaibu Abdullahi Hudu, Albashir Tahir, Nura Abubakar, Sa’ADatu Haruna Shinkafi, Adamu Ahmed Adamu, Mustapha Umar Imam, Abdulgafar Olayiwola Jimoh

    Background: C–X–C motif chemokine ligand 13 (CXCL13) is a critical chemokine for lymphoid organization and immune cell migration during hepatitis B virus (HBV) infection. This systematic review assessed the function of CXCL13 in HBV immunoregulation, pathogenesis, genetic susceptibility, and treatment outcome. Methods: We systematically searched five databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify studies reporting on CXCL13 expression, genetic variants, and clinical outcomes in the context of HBV infection. Thirteen qualified studies were identified and assessed using standard quality appraisal instruments. Results: Data consistently supported the role of CXCL13 in recruiting CXCR5 T and B cells, conditioning germinal center–like reaction(s) as well as antiviral immune responses. Elevated serum CXCL13 levels correlated with better virological response, higher HBsAg clearance, and more favorable response to PegIFNα and nucleos(t)ide analogs. On the other hand, downregulation of CXCL13 was associated with immune tolerance, resistance failure, and disease persistence. Genetically, these polymorphic sites, such as rs355687 and rs76084459, have been associated with vaccine response, the possibility of transplacental transmission, and outcomes of antiviral therapy. Conclusion: CXCL13 is a key immunomodulatory factor in HBV infection and represents an excellent candidate predictive biomarker for treatment response and disease course. Prospective multicenter studies and laboratory research are needed to confirm its usefulness in clinical trials and to investigate therapeutic strategies targeting CXCL13.

  • Open Access

    Comparative Efficacy, Safety, and Cost‐Utility of DPP‐4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real‐World Clinical and Economic Outcomes

    by Abdulgafar Olayiwola Jimoh, Shuaibu Abdullahi Hudu, Anas Ahmad Sabir, Adamu Ahmed Adamu, Nura Bello, Albashir Tahir, Nura Abubakar

    Introduction: The management of type 2 diabetes with metformin as the first‐line therapy has long been established. However, combination therapy of metformin and other oral antidiabetics became necessary to achieve optimal glycemic targets. Recently, the rising cost of these combinations poses a challenge for the healthcare system and patients, particularly in low‐ and middle‐income settings, highlighting the need to balance clinical benefits with economic considerations to ensure access to treatment while maintaining sustainability in patient care. This review aims to compare the efficacy, safety, and cost‐effectiveness of DPP‐4 inhibitors with metformin/metformin with other combinations and metformin alone. Methods: A literature search was performed through databases including PubMed, Scopus, Cochrane, clinicaltrials.gov, and Google Scholar using specific keywords on “type 2 diabetes mellitus management,” “metformin,” “DPP‐4 inhibitors,” “safety,” and “efficacy.” The retrieved studies were screened and selected according to eligibility criteria, followed by data extraction and critical appraisal. The extracted data were synthesized and reported according to the PRISMA guidelines. Results: Thirty‐five eligible studies were included in the review. From the studies, oral antidiabetic options apart from DPP‐4 inhibitors commonly combined with metformin, either as free or fixed‐dose combinations, include SGLT‐2 inhibitors, sulfonylureas, GLP‐1 receptor agonists, insulin, and thiazolidinediones (TZDs). The efficacy of this drug combination is comparable to that of metformin monotherapy, which is more cost‐effective, especially at the beginning of treatment. Where metformin monotherapy fails, the efficacy of an add‐on therapy as a second line depends on the specific target and individual patient differences, and even triple therapy may be recommended for some individuals. The cost‐effectiveness of each combination depended on the cost‐effectiveness model used in the assessment and the nature of the healthcare setting. Discussion: DPP‐4 inhibitors/metformin demonstrate significant HbA1c reduction, but their low cost‐effectiveness hinders patient adherence compared to metformin monotherapy, free drugs, or other combinations. For that, initiating therapy with cost‐effective metformin alone is recommended. Manufacturer‐funded trials highlight a potential bias, necessitating independent research validations.


  • Pharmacological Assessment of Indigofera hochstetteri: Anti-inflammatory and Analgesic Potential

    by Albashir Tahir, Khadija Abdullahi Kobi, Musab Abba Usman, Nura Abubakar, Suleiman Yunusa

  • Open Access

    Exploring the use of complementary and alternative medicine among cancer patients in Africa: A systematic review

    by Abdulgafar O. Jimoh, Shuaibu A. Hudu, Usman M. Aliyu, Adamu A Adamu, Nura Bello, Albashir Tahir, Nura Abubakar


  • Open Access

    Hepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study

    by Shuaibu Abdullahi Hudu, Abdulgafar Olayiwola Jimoh, Sa'ADatu Haruna Shinkafi, Albashir Tahir, Ahmed Subeh Alshrari, Muhammad Tukur Umar, Abdulmajeed Yunusa, Nura Bello, Nura Abubakar

    Hepatitis B virus (HBV) infection remains a critical global health issue, particularly in high‐burden regions with substantial global morbidity and mortality. Despite the efficacy of the hepatitis B vaccine in inducing immunity, a subset of vaccinated individuals fails to achieve adequate immunity. This study investigated the factors influencing immunological response to the hepatitis B vaccine among Nigerian adults. A cohort study was conducted at Usmanu Danfodiyo University Teaching Hospital, Sokoto, involving 307 participants aged 19–60 who had not previously received the hepatitis B vaccine. Data were collected using structured questionnaires assessing demographic characteristics, medical history, and lifestyle factors. Participants received GeneVac‐B, a recombinant hepatitis B vaccine, and 0‐, 1‐, and 2‐month schedule anti‐HB levels were measured post‐vaccination using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (AccuDiag ELISA, Diagnostic Automation/Cortez Diagnostics, Inc., USA) to classify vaccine response. The association between demographic and lifestyle factors and vaccine response was analyzed using IBM SPSS Statistics (Version 25). Of the 307 participants, 209 received the first vaccine dose, and 192 completed all three doses. Anti‐HB quantification revealed that 94.3% of the participants achieved protective immunity (≥ 10 IU/L), while 5.7% were classified as nonresponders (< 10 IU/L). Statistical analysis indicated significant differences in the immune response based on gender ( p = 0.031), with females exhibiting higher mean anti‐HB levels than males. Negative correlations were observed between age and vaccine response ( ρ = −0.296, p < 0.01) and between body mass index (BMI) and response, although the latter was not statistically significant ( ρ = −0.131, p = 0.071). Prior tuberculosis, malaria, measles, smoking, and alcohol use showed no significant impact on the immune response, although recurrent malaria, measles, and smoking were associated with slightly lower mean antibody levels. The study indicates gender and age significantly influence hepatitis B vaccine response, with females and younger individuals demonstrating stronger immunity.